Cabot stock at a glance

Cabot (CBT) has drawn fresh attention after recent trading left the stock at US$81. For investors, that price sits alongside a reported US$3,575.0m in revenue and US$281.0m in net income.

Recent trading has been choppy, with the share price down over 1 day and over the past week. However, a 30-day share price return of 8.83% and a year-to-date share price return of 20.81% sit alongside a 1-year total shareholder return of 8.39%, suggesting that momentum has cooled after a strong run.

If Cabot has you thinking about where else growth or income potential might lie, this is a good moment to scan for other materials and industrials exposure using the 8 top copper producer stocks

With Cabot trading near its recent target price yet still at a slight intrinsic discount, the key question is whether the current valuation leaves upside on the table or if the market is already pricing in future growth.

Price-to-earnings of 14.9x: Is it justified?

Cabot's current P/E of 14.9x sits below both the US Chemicals industry average of 23.8x and a peer average of 30.2x. This points to a market valuation that is lower than many direct comparisons despite the last close at $81.

The P/E ratio compares the share price with earnings per share and is often used for established, profitable companies like Cabot, which reports net income of $281.0m on revenue of $3,575.0m. A lower P/E can mean investors are paying less for each dollar of earnings, although it can also reflect concerns around factors such as slower expected growth or recent earnings pressure.

Cabot is flagged as good value on several fronts, including trading at 5% below the SWS DCF model estimate of future cash flow value at $85.31. Its current Return on Equity of 19.4% is described as low, and net profit margins of 7.9% are below last year's 10.9%. This gives some context for why the market might be cautious. At the same time, Cabot has become profitable over the past 5 years with earnings reportedly growing on average. The latest year shows a decline in earnings and a high level of debt funded entirely through higher risk borrowing sources.

Compared with the broader Chemicals industry, Cabot's P/E of 14.9x is described as good value versus the 23.8x industry average and an even higher 30.2x peer average. This gap suggests the stock is priced more conservatively than many rivals despite having high quality earnings and forecast Return on Equity of 21% in three years. For investors, that contrast between a discounted multiple and the quality and profitability profile is an important tension to weigh alongside the company's high debt load and slower forecast revenue growth of 3.1% per year versus 11.7% for the US market.

Result: Price-to-earnings of 14.9x (UNDERVALUED).

However, that potential upside sits alongside meaningful risks, including high debt levels and revenue growth of 3.12% that trails the broader US market benchmark.

Another view: What does the DCF say?

While the P/E of 14.9x suggests Cabot trades at a discount to the Chemicals industry, the SWS DCF model points to a fair value of $85.31 per share versus the current $81 price. That 5% gap still implies a mild undervaluation, so how comfortable are you with the assumptions behind those cash flow forecasts?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cabot for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Feeling mixed about Cabot after weighing both the risks and the potential rewards? Take a closer look at the underlying data and decide quickly where you stand with the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Cabot has sharpened your thinking, do not stop here. Broaden your watchlist with focused stock ideas built from consistent data instead of noise.

• Target resilience by scanning for 66 resilient stocks with low risk scores that aim to balance potential returns with a steadier risk profile.
• Hunt for value by reviewing the 51 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Get ahead of the crowd by checking the screener containing 21 high quality undiscovered gems before other investors catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.